GlobeNewswire

Aurora Provides Update on Market and Strategic Product Initiatives

Dela

Aurora Solar Technologies Inc. / Aurora Provides Update on Market and Strategic Product Initiatives . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

NORTH VANCOUVER, British Columbia, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Following recent commercial wins in the explosively growing market for advanced PV cells and modules, Aurora Solar Technologies Inc. ("Aurora")("Company")(TSX.V:ACU) (OTCBB:AACTF) (FSE:A82) provides an update on further initiatives to consolidate and expand the company's position in the industry.

Global Market Expansion

With the price of solar energy dropping from $6 per watt to less than $1 per watt in the past 8 years, the outlook for solar energy as an alternative to dirty fossil fuels has never looked brighter. Driving this cost reduction is the launch of new, innovative solar cell designs and processes which could see the market size triple by 2020 (greentechmedia.com). This growth is being driven by investments in clean energy from emerging markets such as China and India where heavy air pollution in major cities is a key strategic problem as well as from leading Western countries such as the U.S., Japan, UK and Canada, and the European Union.

The new solar cell designs such as Monocrystalline PERC, Bifacial and Heterojunction technology are leading the way in improving margins and productivity for cell producers. With significant investments in these three areas by the leading global producers of solar cells, more than 80% of installed solar cell capacity are expected to reflect these designs within the next 7 years (thequartzcorp.com).

Addressing new high-efficiency solar cell markets.

Over the past two years, Aurora has successfully launched Decima and Gemini quality measurement platforms to support Monocrystalline PERC and Bifacial applications. The company has delivered more than 50 of these systems to leaders in the market and continues to expand its customer base and order book by establishing infrared quality measurement as a standard in all new production lines.

As part of the company's leadership strategy in production measurement and control for high-efficiency PV cell manufacturing, Aurora has recently made excellent progress in developing its infrared measurement technology to support Heterojunction Technology (HJT) PV cell manufacturing quality control. (HJT is an ultra high-efficiency solar cell design pioneered by Japan's Panasonic Corp., who is now also partnered with Tesla Inc. for solar products). According to Solar Media Ltd., HJT production capacity is expected to increase by 20 percent this year.

To accelerate this work, Aurora is collaborating with the Solar Energy Research Institute of Singapore (SERIS). SERIS, located at the National University of Singapore, is Singapore's national institute for applied solar energy research, and has strong expertise in HJT R&D.

"SERIS places great value on working with innovative industry partners such as Aurora," said Dr. Armin Aberle, SERIS' CEO. "With our scientific expertise in PV cell design and performance, and our advanced fabrication and analysis facilities, we can assist Aurora in the sophisticated technology development necessary to quickly and effectively address high-growth market segments such as HJT."

Dr. Thomas MUELLER, Head of SERIS' Heterojunction R&D activities, added "We appreciate the opportunity to work with Aurora on developing rapid inline metrology tools to analyse solar cell doped layer carrier concentrations using infrared technology. The ability to gather this information at a large sampling rate in a non-destructive way will lead to much faster process optimization, tighter process control, and higher yield in PV production than is possible with today's probing techniques."

Alignment with Industry 4.0.

Aurora has also aligned its Veritas(TM) visualization, operations and administration system with the emerging Industry 4.0 initiatives in the PV industry. "Industry 4.0" refers to "smart factories" that will ultimately incorporate sensors at every stage of the manufacturing process, cloud computing and cognitive computing for fine-grained process and quality control. According to Dr. Gisela Lanza, Director of the Global Advanced Manufacturing Institute in Suzhou, China, "In China, particularly, there is enormous receptiveness for Industry 4.0. The predominant attitude there is, if I'm investing, then I'm going to spend my money on the very latest technology." This is exemplified by Tongwei Group's recent launch of their 2 Gigawatt "S2" production facility, which they claim to include the world's first Industry 4.0 solar cell production line. In Veritas, Aurora provides facility-wide connectivity to multiple sensors, intelligent display and analysis of process performance and open communication with factory control and resource management systems. The company is also conducting work with leading PV manufacturers to further develop high-value features in Veritas that support Industry 4.0.

Increased capital spending focused on high efficiency solar cell upgrades.

Overall, the Company is observing and benefiting from an unprecedented increase in capital spending focused on the adoption of advanced solar cell structures including Monocrystalline PERC, Bifacial and HJT PV cells.

Finlay Colville, Head of Solar Intelligence for Solar Media, says "The focus on new technology, both due to upgrades and when incorporated in new fab builds, since 2015 looks very different to the technologies that drove PV equipment spending above $10 billion during 2010 and 2011.  At the c-Si stage, the most obvious change has come from PERC, and by 2019, most of the capacity for both p-type mono and multi will have shifted to include rear passivation deposition (PERC), with many of the companies having a clear roadmap to bifaciality. Moving into 2020, this will become mainstream for the industry. Indeed, anyone making c-Si cells with efficiencies below 20% is likely to be left with low-cost selling options then."

"Monocrystalline PERC and Bifacial cell applications drove our business last year and with the addition of Heterojunction optimization solutions to our portfolio, we are well positioned as the solution provider for advanced cell measurement and efficiency optimization," said Michael Heaven, Aurora's CEO.  "The company is discussing new orders for plant expansions with existing customers and conducting testing activities under NDA's with several new prospective clients and expects additions to the order pipeline disclosed in the November 20, 2017 release in the next several weeks and months."

About Aurora Solar Technologies:

Aurora's mission is to deliver exceptional results to the photovoltaic industry through measurement and control of critical processes during solar cell manufacturing.

We measure and map the results of critical cell fabrication processes, providing real-time visualization of material properties and true production tool performance. Our products provide process engineers and production-line operators with the means to rapidly detect and correct process excursions, material faults, limit variations, and optimize processes, thereby eliminating yield-reducing and profit-killing product variation.

We are creating the standard for quality control systems for the global photovoltaic industry. 

Headquartered in North Vancouver, Canada, and founded by experienced leaders in process measurement, semiconductor manufacturing and industrial automation, the Company's shares are listed on the TSX Venture Exchange and trade under the symbol "ACU". The Company was formerly "ACT Aurora Control Technologies". For more information, Aurora's website is located at www.aurorasolartech.com.

For further information contact:

Michael Heaven, P.Eng., MBA
President & Chief Executive Officer
Aurora Solar Technologies Inc.
Phone: +1 (778) 241-5000 
info@aurorasolartech.com

Investor Relations contact:
Nina Lafleur
Phone: +1 (604) 679-9964
info@aurorasolartech.com

Paradox Public Relations
Phone: +1 (514) 341-0408
info@paradox-pr.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Some statements in this news release contain forward­looking information. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. The Company does not assume the obligation to update any forward­looking statement.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aurora Solar Technologies Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum